Period I for Gender Dysphoria (IDENTIFY Trial)

"This clinical trial is searching for 12 volunteers, aged between 18 and 45, who suffer from gender dysphoria. Essential criteria include: willingness to suspend Prep (containing tenofovir alafenamide or tenofovir disoproxil fumarate) 2 weeks before start date and throughout the study; no prior orchiectomy; abstinence from alcohol consumption during the duration of the study; brief interruption of hormonal therapy pre-study and during study period; use condoms for all sexual activity both preceding commencement of research until its completion."

"No, this trial is no longer actively seeking applicants. First posted on February 14th 2022 and last edited on October 18th 2022, alternative studies may now be explored; 646 trials are currently recruiting for gender dysphoria treatments and 168 for the same therapy presently search for participants."

"This clinical trial is no longer seeking participants, and it was last updated on October 18th of 2022. According to information found on clinicaltrials.gov, there are 814 other studies that are currently recruiting patients for their research initiatives."

"Generally, this treatment is used to ameliorate secondary hyperaldosteronism. It has also been known to help manage pharmacotherapy, nephrotic syndrome and breast-related ailments."

"Currently, 168 trials are investigating this therapeutic intervention. Of those studies, 50 have reached Phase 3 of the clinical trial process. While Boylston is the primary hub for these type of experiments in Massachusetts, there are over 2400 other locations running related research."

"In order to be eligible for this study, applicants must lie between 18 and 45 years old. Conversely, there are 183 clinical trials available for minors under the age of 18 and 574 studies with inclusion criteria restricted to individuals over 65."

"As this is a Phase 1 trial, which entails limited data regarding efficacy and safety, our team at Power gauges the treatment's security level to be a 1."